COMMENTARY: Idraparinux was noninferior to standard therapy for deep venous thrombosis but inferior for pulmonary embolism

Woller, Scott C.; Stevens, Scott M.; Elliott, C. Gregory
January 2008
ACP Journal Club;Jan/Feb2008, Vol. 148 Issue 1, p19
Academic Journal
The author comments on the study which examines the effectiveness of idraparinux in treating patients with deep venous thrombosis (DVT) or pulmonary embolism (PE). According to the author, the study provides valuable insight into the benefits and limitations of idraparinux. However, the coagulation cascade presents opportunities to intervene.


Related Articles

  • Idraparinux was noninferior to standard therapy for deep venous thrombosis but inferior for pulmonary embolism.  // ACP Journal Club;Jan/Feb2008, Vol. 148 Issue 1, p19 

    The article presents a study which examines the effectiveness of idraparinux in treating patients with deep venous thrombosis (DVT) or pulmonary embolism (PE). For prevention of recurrent venous thromboembolism, study shows that idraparinux was noninferior to standard therapy in patients with...

  • Pharmacists can help prevent venous thromboembolism. LoBuono, Charlotte // Drug Topics;9/15/2003, Vol. 147 Issue 18, p8 

    Highlights a report concerning deep vein thrombosis (DVT) and pulmonary embolism (PE) in the United States. Underutilization of regimens for the prevention of venous thromboembolism (VTE); Progress in clinical trials and guidelines for the prophylaxis and treatment of VTE; Difficulties in...

  • Superficial Venous Thrombosis and Venous Thromboembolism. Decousus, Hervé; Quéré, Isabelle; Presles, Emilie; Becker, François; Barrellier, Marie-Thérèse; Chanut, Myriam; Gillet, Jean-Luc; Guenneguez, Hervé; Leandri, Christine; Mismetti, Patrick; Pichot, Olivier; Leizorovicz, Alain // Annals of Internal Medicine;2/16/2010, Vol. 152 Issue 4, following p218 

    Background: Superficial venous thrombosis (SVT) is perceived to have a benign prognosis. Objective: To assess the prevalence of venous thromboembolism in patients with SVT and to determine the 3-month incidence of thromboembolic complications. Design: National cross-sectional and prospective...

  • Clinical overview of venous thromboembolism. Schellack, Gustav; Modau, Tumelo; Schellack, Natalie // South African Pharmaceutical Journal;2015, Vol. 82 Issue 10, p21 

    Venous thromboembolism (VTE) encompasses two vascular conditions that are of significant importance, namely deep vein thrombosis (DVT) and pulmonary embolism (PE). DVT is also the most common cause of PE. Medical and surgical patients, and individuals who are at increased risk of developing VTE...

  • Safety Profile of Different Low-Molecular Weight Heparins Used at Therapeutic Dose. Gouin-Thibault, Isabelle; Pautas, Eric; Siguret, Virginie // Drug Safety;2005, Vol. 28 Issue 4, p333 

    Low-molecular weight heparins (LMWHs) have been shown to be as safe and effective as unfractionated heparin (UFH) for the treatment of acute venous thrombosis and non-life-threatening pulmonary embolism. Different reports have shown that LMWHs may also be used to treat patients with unstable...

  • Right-Sided Cardiac Thromboembolism and Its Successful Treatment with Streptokinase: Case Report. Matana, Ante; Mavrić, Žarko; Fischer, Fedor // Angiology;Aug1992, Vol. 43 Issue 8, p697 

    A sixty-eight-year-old woman with a clinical diagnosis of pulmonary embolism and large right-heart embolus on echocardiography Is presented. Because of the critical clinical condition of the patient and the inability to perform surgical intervention, thrombolytic treatment (streptokinase) was...

  • Infection DVT risk.  // Pulse;4/6/2006, Vol. 66 Issue 14, p16 

    The article reports on a British general practice research which suggests that the risk of developing venous thromboembolism is significantly increased after infection. The study found that risk of deep vein thrombosis and pulmonary embolism was doubled after acute urinary tract or respiratory...

  • Factor V HR2 haplotype: a risk factor for venous thromboembolism in individuals with absence of Factor V Leiden. Otrock, Zaher K.; Taher, Ali T.; Shamseddeen, Wael A.; Zaatari, Ghazi; Bazarbachi, Ali; Mahfouz, Rami A. // Annals of Hematology;Dec2008, Vol. 87 Issue 12, p1013 

    Venous thromboembolism (VTE), including deep venous thrombosis (DVT) and pulmonary embolism (PE), occurs secondary to a number of hereditary and acquired disorders of hemostasis. A recently recognized polymorphism in Factor V (FV) gene H1299R (also named HR2) has been reported to be a possible...

  • Thromboembolic Prophylaxis in Blunt Traumatic Intracranial Hemorrhage: A Retrospective Review. DEPEW, ARON J.; HU, CHARLES K.; NGUYEN, ANDRE C.; DRIESSEN, NATALIE // American Surgeon;Oct2008, Vol. 74 Issue 10, p906 

    There are few data in the literature on venous thromboembolic (VTE) prophylaxis for the traumatic population with intracranial hemorrhage (ICH). We reviewed our institutional experience and compared the incidence of deep vein thrombosis and pulmonary embolism in patients with ICH receiving...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics